Publications
Several of the novel alterations induced cancerous phenotypes in cell lines and mouse xenograft models and demonstrated sensitivity to tyrosine kinase inhibitors. Stratifying ALL patients may improve clinical outcomes through the use of therapies targeted to the specific genetic alteration.
In the largest pediatric cancer genome sequencing effort reported to date, TARGET ALL researchers sequenced 120 candidate genes in 187 high-risk childhood B-precursor acute lymphoblastic leukemias (HR B-ALL).
In a letter published in Nature Genetics, pediatric researchers found that Native American ancestry is genetically linked with an increased risk of relapse in childhood acute lymphoblastic leukemia (ALL), the most common cancer in children.
Through unsupervised clustering of gene expression profiling, TARGET researchers discovered eight unique cluster groups among patients with pediatric high-risk B-precursor acute lymphoblastic leukemia (ALL).
Leaders from the NCI Cancer Therapy Evaluation Program (CTEP) and the Children’s Oncology Group provided an overview of the most current childhood cancer statistics.
TARGET researchers used gene expression profiling to improve their ability to predict the outcome of children with high-risk B-precursor acute lymphoblastic leukemia (ALL).
Researchers identified a poor prognostic subgroup of pediatric BCR-ABL1-negative ALL patients and reported that the JAK-mutated cases had a gene expression signature similar to BCR-ABL1 pediatric ALL and suggested inhibition of JAK signaling as a target for therapeutic intervention.
Scientists identified more than 50 recurring copy-number abnormalities in a cohort of patients with B-cell progenitor ALL. Abnormalities were found in genes that encode regulators of B-cell development, PAX5 and IKZF1, a gene that encodes the lymphoid transcription factor IKAROS.
Pages
